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ABSTRACT OF THESIS
ANTIRESORPTIVE BONE THERAPY USE IN ADVANCED LUNG CANCER AND
ASSOCIATED OUTCOMES
Background/Rationale: Studies have shown antiresorptive agents decrease skeletal
related events in metastatic non-small cell lung cancer. However, two prevalence studies
have found low utilization rates of antiresorptive therapy in advanced lung cancer. The
first study reported a rate of 14.8% during the 1995-2009 time period, while the second
study reported a 33% usage rate during the time frame of 2002-2011. We believe these
low utilization rates are associated with the poor prognosis of these patients. The
prognosis of advanced lung cancer has improved significantly since these trials were
conducted, and the utilization of denosumab has not been evaluated. We hypothesize that
intravenous antiresportive bone therapies are underutilized in patients with metastatic
lung cancer.
Objectives: To characterize the utilization of antiresportive therapies in patients with
metastatic lung cancer and to evaluate predictive factors in their initiation.
Methods: This study was a retrospective analysis of EHR data from the University of
Kentucky Enterprise Data Warehouse (UKEDW) linked to Kentucky Cancer Registry
(KCR) containing patients from 1/1/2013 to 1/31/2020. Patients diagnosed with
metastatic lung cancer are included with “index date” being date of first systemic
treatment. Key exclusion criteria included lack of systemic therapy provided at UK.
Incidence of antiresorptive bone therapy initiation was measured. Descriptive statistics
and multivariate logistic regressions were performed to assess factors predicting use and
selection of agent.
Results: Over the study time period, only 16.3 % of patients who received their first
systemic therapy at UK were initiated on an antiresorptive bone medication, with
denosumab being the primary agent used (~65%). Logistic regression analysis shows that
patients with bone metastasis present at diagnosis of stage IV NSCLC had 4.26 times the
odds of receiving an antiresorptive bone medication (95% [CI: 2.146,8.442]) than those
who did not have bone metastasis at diagnosis.
Conclusions: For metastatic non-small cell lung cancer patients receiving their first
systemic therapy at the University of Kentucky, antiresorptive bone therapies are being
underutilized with the primary predictor of use as bone metastasis at diagnosis.
KEYWORDS: Real World Evidence, Oncology, Non-Small Cell Lung, Bone Health
Noor Naffakh
03/19/2020
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CHAPTER 1. INTRODUCTION
With a current 5-year survival rate of around 20.5% overall and 5.8% for distant
disease, lung cancer is the leading cause of cancer death and the second most commonly
diagnosed cancer in the world [1, 2]. Although the prognosis of the disease seems grim,
survival rates have shown a steady increase since the 1980s, with a concomitant decrease
in incidence over the last 10 years by approximately 2.1%. Lung cancer is divided into
two main subtypes: small cell and non-small cell [1]. Non-small cell lung cancer,
abbreviated as NSCLC, can be further divided into adenocarcinoma, squamous cell
carcinoma, or large cell (undifferentiated) carcinoma [3]. Regardless of the type of cancer
detected, staging a patient is important in order to determine prognosis and the best
treatment path to take. Furthermore, genetic screening is also an important factor in
determining the presence of targetable mutations with therapy. While surgery is the most
effective treatment modality in resectable cancer, patients with advanced non-operable
disease with targetable mutations or programmed death ligand-1 (PD-L1) overexpression
may benefit significantly from targeted or immunotherapies. These medications fall
under the umbrella of precision medicine and have significantly increased the expected
progression free survival and overall survival for metastatic NSCLC as compared to
standard chemotherapy [4]. Additionally, the recent FDA approval of these agents for
NSCLC has increased utilization, showing further promise in improving overall survival
rates.
Evolution of Standard of Care for NSCLC
Over the past two decades, there have been several pivotal trials performed and
therapies approved for NSCLC. Prior to the advent of targeted and immunotherapies,
cytotoxic chemotherapy was the standard of care for advanced lung cancer. In 1994, a
meta-analysis analyzing survival of advanced NSCLC patients receiving chemotherapy
versus best supportive care showed that the median survival of 3.9 months for patients
receiving best supportive care only increased to a median survival of 6.7 months with
chemotherapy [5]. This indicates the extremely poor prognosis of advanced lung cancer
patients, regardless of the administration of systemic chemotherapy. In 2002, Schiller et.
al. published a study analyzing four chemotherapy regimens in 1155 eligible advanced
1

NSCLC patients in order to assess the combination of third generation chemotherapy
agents with a platinum-based compound (platinum-doublet) on survival. Combinations of
cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel were
compared to cisplatin and paclitaxel. The study found a median overall survival of 7.9
months which did not differ significantly among any of the four groups [6].
In 2004, tyrosine kinase inhibitors gefitinib and erlotinib showed positive results
against first-generation epidermal growth factor receptor (EGFR) mutations, with
gefitinib showing longer progression free and overall survival than chemotherapy in
advanced lung (stage IIIB and IV) cancer patients in 2009 (PFS: 10.8 months versus 5.4
months; OS: 30.5 months versus 23.6 months) [7, 8]. Other therapies that targeted ALK,
ROS1, and BRAF rearrangements soon followed, greatly increasing median progression
free and overall survival in patients with targetable driver mutations (see figure 1.1 for
timeline). The global phase III ALEX trial which began in August of 2014 aimed to
compare tyrosine kinase ALK inhibitors alectanib versus standard of care crizotinib, in
previously untreated ALK positive advanced NSCLC patients. While initial trial results
showing superior efficacy and lower toxicity of alectanib to crizotinib were published in
2017, a recent trial update has reported median progression-free survival (PFS) for
alectanib as 34.8 months versus 10.9 months with crizotinib. Furthermore, because the 5year overall survival (OS) endpoint has not yet been reached, the update has reported that
at 4 years, 62.5% of the patients in the alectanib group were still alive (52% with
crizotinib). Compared to the aforementioned 5.2% overall 5-year survival rate, targeted
therapies present an unprecedented survival advantage for patients with advanced
NSCLC [9-12].
The final therapy class that has changed NSCLC standard of care includes
immune checkpoint blockers (immunotherapy). In 2015, PD-1 inhibitor pembrolizumab,
was shown to be better than docetaxel in second line metastatic NSCLC. One year later
(2016), pembrolizumab was further approved for first line monotherapy of PDL positive
metastatic NSCLC [7]. The KEYNOTE-189 trial showed an estimated 12-month survival
rate of 69.2% [95% CI: 64.1, 73.8] in the pembrolizumab-combination group as
compared to 49.4% in the placebo-combo group [95% CI:0.38,0.64] [13]. In 2017,
pembrolizumab was further approved for first line treatment with chemotherapy in
2

metastatic NSCLC [4, 7]. In September 2018, the updated KEYNOTE-189 median OS
was 22.0 months (95% CI : 19.5 to 25.2) in the pembrolizumab-combination group
versus 10.7 months (CI: 8.7 to 13.6) in the placebo-combination group with a median
PFS of 9.0 months (95% CI: 8.1 to 9.9) months and 4.9 (95% CI: 4.7 to 5.5) months,
respectively [14].
In a disease that had a prognosis of about half a year with treatment just one
decade ago to now having patients living more than a year with no progression,
immunotherapy and targeted therapy have paved the way of hope for many advanced
non-small cell lung cancer patients.
Figure 1.1 Timeline of Pivotal Trials and Drug Approvals for NSCLC Treatment [7]

Bone Metastases and Skeletal Related Events
The average age of diagnosis of non-small cell lung cancer is 70 years old with
the majority of patients (57%) presenting with stage IV distant disease that has
metastasized to a region outside of the lungs [1, 15]. The bones are one of the most
common sites of metastasis (20-30%) and their involvement has been correlated with an
increased incidence of skeletal related events or SREs [16, 17]. These may include
hypercalcemia, bone fractures, spinal cord compression, or bone pain requiring local
radiation. Normal bone is constantly being remodeled by two types of cells: osteoclasts
and osteoblasts. While osteoblasts build and re-mineralize bone, osteoclasts absorb and
break down bone. An imbalance of one of these processes can lead to either excessive
buildup or breakdown of the bone, which can lead to the aforementioned skeletal related
3

complications. Bone metastases in cancer patients can be characterized as osteolytic,
osteoblastic or mixed bone lesions. In NSCLC, bone metastases typically occur due to
osteolytic lesions which manifest due to an imbalance of osteoclast resorption of the bone
rather than tumor meditated bone destruction [18]. Bone metastases can cause a
significant amount of pain and discomfort for the patient (commonly treated with opioid
analgesics), further decreasing patient quality of life [19-21].
A Comparison of Antiresorptive Bone Therapies
Pamidronate
Pharmacology:
Pamidronate disodium is a bisphosphonate that inhibits resorption of the bone by
binding to calcium phosphate (hydroxyapatite), seemingly blocking the mineral’s
dissolution. The agent has also been shown to inhibit excessive tumor induced
osteoclastic activity in animal models without inhibiting bone formation and
mineralization. The half-life elimination of pamidronate is 28 ± 7 hours whereas half-life
in bone is estimated at 300 days [22]. Studies using pamidronate for osteolytic lesions in
breast cancer and multiple myeloma dosed pamidronate disodium at 90 mg given every
3-4 weeks [23]. As pamidronate is renally eliminated, the medication becomes renally
toxic when administered too quickly. In order to mitigate this adverse event, the 2007
American Society of Clinical Oncology clinical practice guideline recommends clinicians
reduce initial pamidronate dose and administer infusion over a minimum of 2 hours
(especially in patients with pre-existing renal impairment) [24].
Efficacy:
Pamidronate has been shown to be effective for bone metastases in breast and
prostate cancers and multiple myeloma [22], and although not specifically approved for
lung cancer, it is commonly used for other solid tumor patients as it was the first IV
bisphosphonate approved. One retrospective analysis performed in 2009, did aim to
characterize the tolerability of the bisphosphonate in the NSCLC population, however,
the study had clear limitations including unbalanced study groups and a small population
size. Nonetheless, pamidronate appeared to be well tolerated and safe but no clinical
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conclusions could be made with regard to its efficacy compared to zoledronic acid in
metastatic NSCLC [25].
Zoledronic Acid
Pharmacology:
Zoledronic acid (ZA) is an injectable bisphosphonate that inhibits osteoclast
mediated bone resorption by specifically targeting the enzyme farnesyl pyrophosphate
synthase. Zoledronic acid has a strong binding affinity to bone mineral with a high
turnover rate. After IV infusion, ZA rapidly partitions to bone undergoing osteoclast
resorption allowing the drug to target areas of bone metastases [26]. ZA reaches a
maximum concentration in the body 24 hours after infusion, and its 146-hour half-life
constitutes that it be administered once every 28 days. Furthermore, zoledronic acid has a
less renally toxic profile than pamidronate, allowing for faster infusion time no shorter
than 15 minutes. Hypocalcemia is a noted side effect, and calcium levels should be
monitored with ZA administration. Cases of osteonecrosis of the jaw (ONJ) have been
reported and can be mitigated by avoiding invasive dental procedures such as tooth
extraction [26].
Efficacy:
Numerous randomized controlled studies have demonstrated zoledronic acid’s
effectiveness in delaying time to SREs in patients with metastatic NSCLC [27, 28]. One
pivotal study by Rosen et al. looked at the long-term effects of 4 mg zoledronic acid
administration over 21 months compared to placebo in NSCLC patients with bone
metastases. This trial found a 31% reduced risk [HR 0.692, P=0.003] of developing an
SRE as well as a longer median time to first SRE development (236 days 4mg, 155 days
placebo) [29]. Patients in the zoledronic acid group also reported bone pain less
frequently than the placebo group [29] with findings from studies by Van Moos and
Henry et al. corroborating reductions in pain or opioid analgesic use secondary to bonetargeted agent administration [30]. A systematic review assessing the effects of
bisphosphonates on bone pain and quality of life noted that a decrease in stable analgesic
consumption was found in 58% - 75% of patients in four single arm studies [31]. Other
studies have also demonstrated that the bisphosphonate may contain antitumor properties,
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as it has been shown to act synergistically with chemo, targeted, and immunotherapies
potentially increasing overall survival (OS) [32-35].
Denosumab
Pharmacology:
Denosumab is a human monoclonal antibody that binds to RANKL (receptor
activator of NFκB ligand), a protein that is essential for the survival of osteoclasts.
RANKL is responsible for activating the RANK receptor that is located on osteoclasts
and their precursors [36]. By inhibiting the RANKL-RANK interaction, denosumab
subsequently prevents the maturation and survival of osteoclasts, therefore reducing bone
turnover [37].
Efficacy:
Six head-to-head randomized controlled trials have been performed comparing
the efficacy of zoledronic acid and denosumab for the prevention of skeletal-related
events in patients with solid tumors [38]. A systematic review published in 2012
comparing three of the identically designed phase III trials showed an increased time to
first SRE and less total SREs in favor of denosumab. While zoledronic acid and
denosumab appeared to be equivalent in overall survival and disease progression in this
analysis overall, (HR= 0.98; 95% CI [0.91-1.06]), (HR=1.02, 95% CI [0.96-1.09]) [39],
an exploratory sub-group analysis of one of these trials by Scagliotti et al. has shown a
median overall survival benefit in favor of denosumab (9.5 months versus 8 months with
ZA; HR =0.78, p = 0.01) in patients with NSCLC. This study also found a lower rate of
serious adverse events in the denosumab group versus ZA group (66% versus 72.9%),
with similar incidence of ONJ. Patients treated with denosumab had higher rates of
hypocalcemia (8.6% versus 3.8%) [40].
A Comparison of Guidelines
Two major guidelines that comment on the use of these bone therapy agents
include those from the National Comprehensive Cancer Network (NCCN) from the
United States and those from the European Society of Medical Oncology (ESMO). Four
points of comparison among the two guidelines include selection of bone therapy agent,
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dosing, time of agent initiation, and optimal duration of therapy. (See Table 1.1 for
summary of recommendations).
Bone Therapy Agent Selection:
Currently, the National Comprehensive Cancer Network (NCCN) guidelines
recommend for the use of “orthopedic stabilization and palliative external beam radiation
therapy” for bone metastases if there is a risk of fracture, and a ‘consideration’ for the use
of bisphosphonate therapy (zoledronic acid or pamidronate) or denosumab in patients
with metastatic NSCLC [41]. Details of therapy are left up to clinical judgement among
the three agents, however the guideline does reference the aforementioned Scagliotti et al.
study showing a survival benefit in favor of denosumab to ZA (9.5 months versus 8
months), and points out that the FDA has only approved “zoledronic acid and denosumab
in patients with bone metastases with solid tumors” [40, 41]. To compare to the NCCN
guidelines, the ESMO guidelines go into more detail of the different trials performed in
each of the solid tumor states, and how the dosing and recommendations compare to each
other. More specifically, the ESMO guidelines cite in detail the phase III trial that
compared zoledronic acid to denosumab in 1776 non-breast/prostate solid tumor patients,
stating that although the trial did not exclusively contain lung cancer patients, a large
proportion (40%) had NSCLC, and showed an extended time to first SRE from 16.3 to
20.6 months, thus recommending therapy for patients with life expectancy >3 months and
perceived high SRE risk. Similar to NCCN, the ESMO guidelines maintain the choice of
antiresorptive bone therapy agent (zoledronic acid, denosumab, or pamidronate) open,
while emphasizing that although ZA has not been proven superior to pamidronate per se
(except for post-hoc analysis in breast), denosumab has shown greater efficacy to ZA in
trials with pre-specified end-points [42].
Dosing:
NCCN NSCLC guidelines do not specify dosing of bisphosphonates or
denosumab, leaving details of therapy up to clinical judgement [41]. With regard to
dosing, ESMO cites the doses used in each of the bone-targeted therapy studies based on
efficacy and regulatory approval. For all solid tumors, the guideline lists zoledronic acid
4 mg i.v. every 3-4 weeks and denosumab 120 mg subcutaneously every 4 weeks.
7

Pamidronate 90 mg i.v. every 3-4 weeks only received regulatory approval for breast
cancer and multiple myeloma [42].
Time of Bone Therapy Initiation:
With regard to therapy initiation, NCCN NSCLC guidelines state that denosumab
or intravenous bisphosphonates can be considered in patients with bone metastases [41].
ESMO guidelines make a more definitive recommendation on bone therapy initiation
stating that bone-targeted therapy should be started at diagnosis of metastatic bone
disease [42].
Optimal Duration of Therapy:
Both NCCN and ESMO guidelines state that optimal duration of antiresorptive
bone therapy is unknown, although ESMO guidelines still recommend that therapy “should
continue indefinitely and throughout the course of the disease” [41, 42].
With the numerous differences in recommendations between and within guidelines
along with clear uncertainty with regard to optimal duration of therapy, patterns of
antiresportive bone therapy use in real world practice is a necessary point of exploration.
Table 1.1: Summary of Guideline Recommendations Regarding Bone Therapy Use in
NSCLC
Agent Selection

Dosing

NCCN & ESMO

NCCN: Does not specify

Leave choice between agents open but
cite trials favoring denosumab over
zoledronic acid

ESMO:
zoledronic acid 4 mg i.v. every 3-4 weeks
denosumab 120 mg s.c. every 4 weeks
pamidronate 90 mg i.v. every 3-4

Time of Initiation
NCCN: ‘consideration’ for the use of
bisphosphonate or denosumab in patients
with bone metastases.
ESMO: start at diagnosis of metastatic
bone disease

Optimal Duration
NCCN & ESMO: optimal duration of
therapy is unknown
ESMO: but therapy “should continue
indefinitely and throughout the course of
the disease”.

8

Literature Outlining Utilization of Antiresorptive Bone Therapies
There appear to be two studies that have assessed the prevalence and characteristics
of metastatic lung cancer patients utilizing antiresorptive bone therapies. The first study
looked at IV zoledronic acid or pamidronate administration prior to or after an SRE in
breast, prostate, and lung cancers using data from two large US health systems from
1/1/1995 to 12/31/2009. The authors identified 332 patients with lung cancer and bone
metastases and determined that only 14.8% of those patients received IV bisphosphonates
[43]. The prevalence of denosumab use was not evaluated. The authors of this study also
conducted a similar analysis of rates of skeletal related events in lung cancer patients
from the same time frame and health system datasets. They found that 41.0% of NSCLC
patients had an SRE at 6 months post diagnosis of bone metastases [20].
The second study utilized the Truven Health MarketScan® Commercial and
Medicare databases from 2002-2011 [44]. This study was published in 2014 and the
authors claim to be the first to characterize IV bone medication “practice patterns” in
lung, prostate, and breast cancer patients with bone metastases using ICD-9 codes. This
study identified 10,982 eligible lung cancer patients and found similar utilization results
as the study above. Of the three solid tumor disease states examined, lung cancer patients
received IVB’s the least frequently (33% versus 59% for breast and 43% for prostate) and
had the highest rate of IVB therapy treatment discontinuation at 12 months (83% lung
versus 56% prostate and 45.8% breast). One limitation of this study included the fact that
denosumab was dropped from analysis. It was FDA approved for the prevention of
skeletal related events in November of 2010, and not enough claims were present to
examine patterns of use among the three cancers [36, 44]. Another limitation was the
non-differentiation of non-small cell lung cancer versus small cell lung cancer due to the
nature of the claim’s dataset.
Overall, both studies found an underutilization of bone medication use in metastatic
lung cancer patients and there remains a large gap in knowledge of the true prevalence of
bone health medication use in this population [43, 44]. The first study was performed
during a time span that predated NCCN guideline recommendations of administering
bone health medications for the NSCLC population, and both studies did not account for
9

the use of denosumab, which has shown superiority to zoledronic acid in three trials [41,
45, 46]. Furthermore, as both studies used date of bone metastasis diagnosis as the
primary index, patients who received intravenous bone therapies without having a
diagnosis of bone metastasis were not included in the final analysis, narrowing the view
of real-life practice patterns. As these medications are currently in the guidelines,
prescribing and administration patterns of intravenous bone therapies may have also
changed and should be characterized, as actual rate of utilization in the NSCLC
population is currently unknown.
Current information is also outdated as new targeted agents and immunotherapies
have been approved since both prevalence studies were performed. Many of these
therapies show an increased overall survival time in this population, so maintaining a
good quality of life is essential in those additional months with a goal of delaying time to
skeletal related event. Additionally, some targeted therapies have shown synergistic
effects alongside bone-health medications with respect to tumor response and survival
time, making the effect of their combinations an interesting point for exploration [47].
Finally, there is anecdotal evidence from University of Kentucky HealthCare (UKHC)
that these medications are currently only being given to less than 20% of eligible nonsmall cell lung cancer patients. Contingent on the results, this may be a good area for a
dissemination and implementation (D&I) protocol.

 2020 Copyright: Noor A. Naffakh
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CHAPTER 2. METHODS
Overview
The primary aim of this study is to characterize the utilization of antiresportive
therapies in patients with metastatic non-small cell lung cancer treated at University of
Kentucky HealthCare. Furthermore, as the previously cited prevalence studies excluded
denosumab in their analysis, a sub-aim of the study is to describe the overall utilization of
these therapies broken down by agent (pamidronate, zoledronic acid, denosumab) and by
year (1/1/2013 – 1/31/2020). Finally, as the NCCN guidelines for lung cancer do not
specify the optimal dosage and frequency of these agents in lung cancer, a secondary aim
is to describe trends in antiresorptive therapy usage (dose and frequency) for each agent
and compare the selection of therapy based on age, gender, histology, and region of the
country (urban versus rural). We hypothesize that antiresportive therapies are
underutilized in patients with metastatic lung cancer.
Databases
The Kentucky Cancer Registry (KCR) as well as the University of Kentucky
Enterprise Data Warehouse (UKEDW) were the two databases used to conduct this
study. As established by legislation passed by the Kentucky General Assembly in 1990,
KCR is the official population-based central cancer registry for the Commonwealth of
Kentucky. Every healthcare facility in Kentucky is required to report any cancer case
diagnosis or treatment to KCR through the use of the Cancer Patient Data Management
System (CPDMS) established by the registry. As one of the registries constituting the
National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program,
one of the most ‘accurate and complete population-based cancer registries globally,’ the
Kentucky Cancer Registry has received funding from the program to ensure the
collection of quality data with enhanced and complete follow-up information.
Furthermore, KCR is part of the Centers for Disease Control and Prevention's National
Program of Cancer Registries (NPCR) and submits annually to the North American
Association of Central Cancer Registries (NAACCR) for objective evaluation of
‘completeness, accuracy, and timeliness’. Since 1999, KCR has received Gold status
11

from NAACCR, the highest level of certification, further supporting the rigor of the
dataset [48].
The KCR data provided necessary histological, topographical, and demographic
information that cannot be found in the UK database alone. [See Appendix 1 for KCR
definitions]. Furthermore, the KCR data provided a more standardized, structured, and
holistic collection of cancer diagnosis and treatment types and dates if a patient did not
receive continuous care at one Kentucky facility (due to transfers or treatment at multiple
sites). The initial population pulled from the KCR dataset was used as the source
population and then linked to the UKEDW. UK HealthCare electronic health record
(EHR) data provided detailed information regarding medication administration and
laboratory test results during patient hospital and ambulatory care visits [49]. In order to
conduct this study, access to identifiable private information was needed.
Data Collection
Stage IV non-small cell lung cancer cases from 1/01/2013 – 1/31/2020 were
obtained from the Kentucky Cancer Registry and were linked to information from UK's
Enterprise Data Warehouse. An honest broker from the UK Center for Clinical and
Translational Science (CCTS) data collection team was supplied with patient identified
cancer records, which were then linked to the electronic health records from the EDW by
unique patient medical record number (MRN). Information linked from UKEDW
included encounters containing antiresorptive bone medication administration, lab
information, incidence of skeletal related events, etc. [See Appendix 2 for codes used in
encounter identification] The final dataset provided to the investigators for analysis was
de-identified.
Sample Selection
In order to determine incidence of antiresorptive bone therapy use in the UK stage
IV NSCLC population, a source population needed to be defined. This population was
denoted as the ‘denominator’ population and was limited to those deemed eligible to
receive intravenous antiresorptive bone therapy. A proxy of eligibility included receiving
systemic cancer therapy (chemotherapy or immunotherapy) at University of Kentucky
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HealthCare (UKHC) Markey Cancer Center as an initial inclusion criterion. In order to
capture different snapshots/scenarios of bone therapy use, further population stratification
was performed by the three methods outlined below.
Population 1: Patient’s first systemic treatment was received at UKHC.
Population 2: At least one systemic treatment was received at UKHC.
Population 3: Multiple systemic treatments were received at UKHC.
As Kentucky’s only National Cancer Institute (NCI)-designated cancer center, the
Markey Cancer Center has a large proportion of referrals for treatment, precision
medicine, and clinical trials. Moreover, while many patients may present to Markey for
initial surgical management or treatment, they may be referred out for more convenient
management at partner facilities with closer proximity to the patient’s home. As such, the
methodology of source population stratification is intended to mimic different scenarios
with regard to referral, and likelihood of being able to capture bone medication
administration in a patient that may not have received continuous care at University of
Kentucky.
As defined above, Population 1 is intended to mimic the most commonly
expected scenario, whereby an intravenous antiresorptive bone medication is given close
to first systemic treatment of a patient diagnosed with metastatic lung cancer in
accordance with the guidelines cited above. Population 2 considers that UKHC is a
referral center and attempts to capture a patient treated systemically at UKHC, regardless
of whether it was the first instance, as this patient may have been diagnosed and treated
elsewhere, then referred to UKHC for further management. Population 3 requires that
patients received two or more systemic treatments at UKHC in order to increase the
probability of capturing bone medication use due to increased facility contact points. See
appendix 3 for visualizations of population scenarios.
Statistical Analysis
Descriptive Statistics
Descriptive statistics were performed to describe each patient population from the
three populations outlined above as well as from the overall stage IV NSCLC population
and the subgroup of those patients who did not receive systemic therapy. Variables of
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interest included patient demographics, year of diagnosis, cancer histology, smoking
status, geographic designation (rural versus urban), presence of metastases at diagnosis
(bone, liver, or brain), and average days to first treatment (in general and systemic).
Utilization
Incidence of antiresorptive bone therapy use was determined for each population.
This study was a retrospective analysis with an index date of first systemic therapy for
each of the populations defined above. Incidence of bone therapy medication use was
measured with initiation on same day as chemo/immune systemic therapy, within 1
month of treatment, and at interval points thereafter with affiliated percentiles and
averages. Bone medication administration during an inpatient visit to UKHC with
affiliated corrected serum calcium level of >12 mg/dL (Corrected Ca = serum calcium –
serum albumin + 4) were noted, as antiresorptive bone agents can also be used to treat
hypercalcemia of malignancy. After an incident case of antiresorptive bone medication
use was identified, the associated patient was categorized as an intravenous antiresorptive
bone therapy user. After incidence determination, subsequent patterns of bone medication
use were analyzed with descriptive statics for most common medication, doses, and
dosing frequencies.
Regression Analysis
Finally, a logistic regression was performed to determine factors predicting bone
medication use. This was only done in population one as it is the most expected scenario
of bone medication administration. Bone medication users were determined from the
incident-case flag defined above. Variables of interest included patient demographics,
year of diagnosis, cancer histology, smoking status, geographic designation (rural versus
urban), and presence of metastases at diagnosis (bone, liver, or brain). Sub-group analysis
for patients that presented with bone metastases at diagnosis was also performed. 95%
confidence intervals were reported, and P values < 0.05 were considered to be
statistically significant.
This study was reviewed and approved by the University of Kentucky Institutional
Review Board. Data analysis was completed using SAS Version 9.4 and Microsoft SQL
Server Management Studio v17.7.
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CHAPTER 3. RESULTS
Characteristics of Study Population
Figure 3.1 depicts the study population obtained from the Kentucky Cancer
Registry and subsequently linked to UK electronic health records. 1161 unique patients
were diagnosed with stage IV NSCLC and were seen at UK at some point during the
course of their treatment. Of those patients, 548 or 47% received at least one systemic
treatment of chemotherapy or immunotherapy. 241 of those patients did not receive any
systemic therapy at UK, leading them to be excluded from the three populations of
interest shown in figure 3.2. Overall 307 patients received at least one systemic treatment
at UK, and 295 of those patients received their first systemic treatment at UK. 104
patients received more than one systemic treatment at UK with the majority of this cohort
(101 patients) also receiving their first systemic treatment at UK.
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Figure 3.1 Final Study Population Derived from KCR and Linked to UK EHR Records
Total Starting Population:
Total Cases Diagnosed or Treated at UK

Exclude:

N = 24122

N = 20625
Non-Lung Cancer
Cases

Any Lung Cancer at UK
Exclude:

N = 3497

N = 493
Non-NSCLC cases
NSCLC at UK

Exclude:

N = 3004

N = 1843
Non-Metastatic
NSCLC Cases

Diagnosed with Stage IV NSCLC at UK
N = 1161

Exclude:

(KCR Records Linked to UK Electronic
Health Records)

N = 613
Did Not Receive
Any Systemic
Therapy After
Diagnosis

Received Systemic Therapy
(Chemotherapy or Immunotherapy)
After Diagnosis
N = 548

Exclude:
N = 241
No Systemic
Therapies at UK

At Least One Systemic Treatment at UK
N = 307
(See Figure 3.2 For Further Stratification)
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Figure 3.2 Final Study Population Further Broken Down into Three Population Scenarios

Population 1: Most
commonly expected
scenario - bone
medication is given
close to first systemic
treatment

Population 3: More likely to
capture bone medication use
due to increased contact
points at UK

Multiple
systemic
treatments @
UK
N = 104

First systemic
treatment
@ UK
N = 295

At least 1 systemic treatment
@ UK N = 307

Population 2: What is actually
happening
Descriptive Statistics
Table 3.1 provides descriptive statistics of the over-arching Stage IV NSCLC
population, those who received any systemic therapy in the course of disease treatment,
and those who did not receive systemic therapy. Breakdown of diagnosis by year appears
to be proportioned consistently among years with the exception of 2019, likely due to
incomplete case abstraction by the time the data were pulled as cases take time to be
reported and recorded into the KCR dataset. Overall average age of diagnosis was 63.7
years. Patients who received systemic therapy appeared to have a slightly younger age
distribution than those who did not receive systemic therapy (median = 62 versus 66).
17

There appears to be a slightly larger percentage of males diagnosed with stage IV
NSCLC than females overall (56.6% versus 43.4%), and the predominant race of patients
diagnosed is white (~93%) with a majority of patients classified as cigarette smokers
(~87%). In the overarching population, the proportion of patients living in urban versus
rural areas appears to be very similar, (51% versus 48%), however, it appears that
patients who received systemic therapy were more likely to live in an area with urban
designation (54% versus 44%). In all the stage IV cases diagnosed, the most common
histology was adenocarcinoma (53.6%), with a higher proportion in those who received
systemic therapy (60.8% versus 47.3%). Finally, patients who did not receive systemic
therapy appear to have a higher percentage of bone and liver metastasis at diagnosis than
those who received systemic treatment (37% vs. 33% bone and 19% vs 14% liver). Brain
metastasis at diagnosis is slightly more prevalent in patients who received systemic
therapy; however, the difference between groups appears minimal (41% vs 38%).
Similar to table 3.1, table 3.2 provides descriptive statistics of the three
populations outlined in figure 3.2. Age, sex, race, and tobacco use appear to be similar
across the three groups. Compared to the overall metastatic NSCLC population, patients
who had any systemic therapy at UK appear to be diagnosed at a slightly earlier age
(median 61 vs 64 years). Patients who had multiple systemic treatments at UK appear to
live in an area with urban designation slightly more often than the larger encompassing
population 1 and 2 (68% vs ~66%); however overall, more than half of patients receiving
any systemic treatment at UK appear to live in an urban area. This is higher than the
overall patient population where only about 51% of patients come from urban areas. The
primary histology in all populations was adenocarcinoma (65-68%) and the majority of
patients from each population were considered cigarette smokers or other tobacco users.
Approximately 33-36% of patients presented with bone metastases and 17-19% with liver
metastases at diagnosis. Presentation of brain metastases at diagnosis was significantly
higher for populations 1 and 2 (~45%) as opposed to population 3 (~30%). The average
time from diagnosis to first treatment for each population was ~12 days (median = 4
days), whereas the average time to first systemic treatment was significantly longer.
Populations 1 and 2 had an average of about 60 days from diagnosis to first systemic
treatment, whereas population 3 was shorter at approximately 50 days.
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Table 3.1 Descriptive Statistics of the Over-arching Stage IV NSCLC Population by
those Receiving Any versus No Systemic Therapy
Variable
Calendar Year
Frequency (%)
2013
2014
2015
2016
2017
2018
2019
Age
Mean (SD)
Median (Q1, Q3)
(Min, Max)
Sex
Male
Female
Race
White
Black
Other
Region
Urban
Rural
Unknown
Tobacco Use
Cigarette smoker
Other tobacco user
Never tobacco user
Unknown
Histology
Adenocarcinoma
Squamous Cell
Carcinoma
Other*

Stage IV NSCLC Systemic Therapy
N = 1161
N=548

No Systemic
Therapy
N = 613

181 (15.59%)
197 (16.97%)
192 (16.54%)
174 (14.99%)
215 (18.52%)
159 (13.70%)
43 (3.70%)

97 (17.70%)
98 (17.88%)
104 (18.98%)
85 (15.51%)
90 (16.42%)
59 (10.77%)
15 (2.74%)

84 (13.70%)
99 (16.15%)
88 (14.36%)
89 (14.52%)
125 (20.39%)
100 (16.31%)
28 (4.57%)

63.87 (10.23)
64 (57,71)
(23,97)

61.44 (9.95)
62 (55, 69)
(23, 87)

66.06 (9.99)
66 (58,73)
(37,97)

657 (56.59%)
504 (43.41%)

293 (53.47%)
255 (46.53%)

364 (59.58%)
249 (40.62%)

1086 (93.54%)
67 (5.77%)
8 (99.31%)

511 (93.25)
32 (5.84%)
5 (0.91%)

575 (93.80%)
35 (5.71%)
3 (0.48%)

593 (51.08%)
561 (48.32%)
7 (0.60%)

301 (54.93%)
245 (44.71%)
2 (0.36%)

292 (47.63%)
316 (51.55%)
5 (0.82%)

1022 (88.18%)
17 (1.47%)
73 (6.30%)
47 (4.06%)

480 (87.59%)
3 (0.55%)
41 (7.48%)
24 (4.38%)

542 (88.71%)
14 (2.29%)
32 (5.24%)
23 (3.76%)

623 (53.66%)
251 (21.62%)

333 (60.77%)
112 (20.44%)

290 (47.31%)
139 (22.68%)

287 (24.72%)

103 (18.80%)

184 (30.02%)
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Table 3.1 (continued)
Bone Mets at
Diagnosis
Yes
No
Unknown
Liver Mets at
Diagnosis
Yes
No
Unknown
Brain Mets at
Diagnosis
Yes
No
Unknown

408 (35.14%)
748 (64.43%)
5 (0.43%)

180 (32.85)
368 (67.15%)
-

228 (37.19%)
380 (61.99%)
5 (0.82%)

193 (16.62%)
959 (82.60%)
9 (0.78%)

75 (13.69%)
470 (85.77%)
3 (0.55%)

118 (19.25%)
489 (79.77%)
6 (0.98%)

455 (39.19%)
698 (60.12%)
8 (0.69%)

223 (40.69%)
325 (59.31%)
-

232 (37.85%)
373 (60.85%)
8 (1.31%)

(*Most commonly includes: not otherwise specified (NOS), large cell, neuroendocrine, and
mixed histologies)
Means and standard deviations (in parentheses) are given for continuous variables, whereas
frequencies and percentages (in parentheses) are given for categorical variables.

Table 3.2 Descriptive Statistics of Patients who Received Systemic Treatment by
Population
Variable
Age (years)
Mean (SD)
Median (Q1, Q3)
(Min, Max)
Sex
Male
Female
Race
White
Black
Other
Region
Urban
Rural
Unknown

Population 1
N = 295

Population 2
N = 307

Population 3
N =104

60.86 (9.87)
61.00 (54,68)
(36, 85)

60.84 (9.88)
61.00 (54,68)
(36, 85)

59.61 (10.22)
60.00 (54, 67)
(36, 85)

154 (52.20%)
141 (47.80%)

162 (52.77%)
145 (47.23%)

56 (53.85%)
48 (46.15%)

269 (91.19%)
23 (7.80%)
3 (1.02%)

280 (91.21%)
24 (7.82%)
3 (0.98%)

95 (91.35%)
7 (6.73%)
2 (1.92%)

195 (66.10%)
98 (33.22%)
2 (0.68%)

201 (65.47%)
104 (33.88%)
2 (0.65%)

71 (68.27%)
33 (31.73%)
-
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Table 3.2 (continued)
Tobacco Use
Cigarette smoker
Other tobacco user
Never tobacco user
Unknown
Histology
Adenocarcinoma
Squamous Cell
Carcinoma
Other*
Days from
Diagnosis to
Treatment One
Mean (SD)
Median (Q1, Q3)
(Min, Max)
Days from
Diagnosis to First
Systemic Treatment
Mean (SD)
Median (Q1, Q3)
(Min, Max)
Bone Mets at
Diagnosis
Yes
No
Liver Mets at
Diagnosis
Yes
No
Unknown
Brain Mets at
Diagnosis
Yes
No

259 (87.80%)
3 (1.02%)
24 (8.14%)
9 (3.05%)

268 (87.30%)
3 (0.98%)
25 (8.14%)
11 (3.58%)

86 (82.69%)
13 (12.5%)
4 (3.85%)
1 (0.96%)

193 (65.42%)
50 (16.95%)

200 (65.15%)
50 (16.29%)

71 (68.27%)
18 (17.31%)

52 (17.63%)

57 (18.57%)

15 (14.42%)

11.98 (19.25)
4.00 (0,17)
(0,148)

11.69 (18.96)
4 (0,16)
(0,148)

12.42 (17.86)
4.00 (0,19)
(0,78)

60.82 (58.85)
50.00 (33,69)
(3, 578)

60.23 (58.16)
50 (33,68)
(3, 578)

54.30 (52.24)
41.00 (28.5, 61.5)
(3, 397)

100 (33.90%)
195 (66.10%)

104 (33.88%)
203 (66.12%)

37 (35.58%)
67 (64.42%)

50 (16.95%)
243 (82.37%)
2 (0.68%)

52 (16.94%)
252 (82.08%)
3 (0.98%)

20 (19.23%)
84 (80.77%)
-

133 (45.08%)
162 (54.92%)

137 (44.63%)
170 (55.37%)

31 (29.81%)
73 (70.19%)

(*Most commonly includes: not otherwise specified (NOS), large cell, neuroendocrine, and
mixed histologies)
Means and standard deviations (in parentheses) are given for continuous variables, whereas
frequencies and percentages (in parentheses) are given for categorical variables.
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Bone Therapy Utilization
Table 3.3 shows incidence of bone therapy initiation divided by population and
agent. Of patients who received their first systemic therapy at UK, only 48 or 16.3 %
were initiated on a bone therapy agent at UK in the course of their disease treatment. The
most common agent used was denosumab (65%), with zoledronic acid and pamidronate
constituting the other 35% in a nearly equal proportion. As population 1 and 2 are
concentric, the distribution of bone therapy use for both populations was nearly identical,
with population 2 containing only one more denosumab user than population 1. As such,
population 2 was excluded from further descriptive analyses. Population 3, which
consists of patients receiving multiple systemic therapies at UK, had a higher
proportional; incidence of bone therapy initiation (22.12%) than the other two
populations, with an even higher proportion of denosumab use (82%) as compared to
zoledronic acid and pamidronate. Figure 3.3 shows that there is not a clear pattern in
bone therapy initiation with regard to time. When looking at population 1, there appears
to be no use in 2013, low initiation in 2014, initiation appears steady in 2015-2017, with
a spike in initiation for 2018. Initiation in 2019 appears low likely due to the incomplete
case abstraction to KCR as mentioned above. Population 3 shows a similar spike in bone
therapy initiation in 2018 with nearly 43% of all bone therapy initiation occurring in that
year.
Table 3.3 Overall Initiation of Antiresorptive Bone Therapy by Agent and Population
Agent

Denosumab

Zoledronic
Acid

Pamidronate

All agents Frequency
(% of total population)

Population 1

31

8

9

48 (16.3%)

32

8

9

49 (15.96%)

19

2

2

23 (22.12%)

N= 295
Population 2
N = 307
Population 3
N =104
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Figure 3.3 Incidence of Antiresorptive Bone Therapy Initiation by Year for Populations 1
and 3

Table 3.4 shows the incidence of bone therapy initiation from time of first
systemic treatment for populations 1 and 3 while table 3.5 shows the affiliated quantiles
of days to bone therapy initiation since first systemic treatment. For population 1, a large
proportion of patients were initiated on a bone therapy within 30 days of their first
systemic treatment, with 25% of them beginning the therapy before or on the day of
systemic therapy. Approximately 50% of population 1 patients began bone therapy within
2 months (60 days) of first systemic therapy, but nearly 25% of patients were not initiated
on a bone therapy until after the 6-month post-first systemic therapy mark.
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Comparatively, population 3 had a smaller proportion of patients initiated on bone
therapies within 30 days of first systemic treatment, with only 10% of the population
beginning both therapies on the same day. Approximately 50% of population 3 were
started on a bone therapy within 85 days of first systemic therapy, with almost 30% still
not having initiated bone therapy at 6 months post-first systemic.
Table 3.4 Incidence of Antiresorptive Bone Therapy Use from Time of First Systemic
Treatment (Chemotherapy or Immunotherapy) for Populations 1 and 3
Population

Population 1

Within 30
days from
1st systemic

Within 60
days from
1st systemic

Within 90
days from
1st systemic

Within 180
days from
1st systemic

More than
180 days
from 1st
systemic

18 (37.50%) 5 (10.42%)

7 (14.58%)

6 (12.5%)

12 (25%)

4 (17.39%)

5 (21.74%)

3 (13.0%)

7 (30.4%)

N = 48
Population 3

4 (17.39%)

N = 23

Table 3.5 Quantiles and Affiliated Days of Bone Therapy Initiation for Populations 1 and
3
Level Quantile

Population 1

Population 3

N = 48

N = 23

Days since first systemic therapy
100% (Max)

1298

770

95%

696

696

90%

483

563

75% (Q3)

183

328

50% (Median)

61

85

25% (Q1)

0

43

10%

0

0

-32

0

0% (Min)
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Table 3.6 shows all of the doses and frequencies of bone medication use for
populations 1 and 3. The most common agent used in both groups was overwhelmingly
subcutaneous denosumab, 120 mg given every 4 weeks. This dose and frequency
constituted nearly half of all schedules. In population 1, one patient had a schedule of
every 6 weeks, and another patient received a 60 mg dose at an unknown frequency.
Zoledronic acid was typically administered as a 4 mg dose, with frequency unspecified.
One patient received a dose of 3.3 mg which was likely due to renal adjustment.
Pamidronate was given as either 60 mg or 90 mg infusions of varying lengths (2-24
hours). Population 3 showed a similar pattern with over half of patients receiving
denosumab, 120 mg every 4 weeks.
Table 3.6 Common Doses and Frequencies of Bone Medication Use for Population 1 and
3
Population 1
Common
dose/route/frequency
Denosumab
60 mg
120 mg
Zoledronic Acid
3.3 mg
4 mg
Pamidronate
30 mg
60 mg
90 mg
Population 3
Common
dose/route/frequency
Denosumab
120 mg
Zoledronic Acid
4 mg
Pamidronate
60 mg
90 mg

No frequency
provided
1
8
1

Every 30 days

Every 42 days
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1

7

-

-

-

No frequency
provided

Every 30 days

Every 42 days

4

15

2
7
(1 hypercalcemia)

2
1
1
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Regression Analysis
The following tables show a logistic regression performed in order to determine
factors predicting the initiation of antiresorptive bone therapy agents for patients who
received their first systemic therapy at UK (population 1). The dependent variable of
interest was initiation of bone therapy during disease course treatment (yes/no). Meancentered diagnosis age, sex, rural vs urban geographic designation, histology, bone, liver,
and brain metastases were all parameters included in the model. Likelihood ratio, Score,
and Wald’s Chi-square tests indicate that at least one of the predictors’ regression
coefficient is not equal to zero in this model (p < 0.05) leading us to reject the null that all
regression coefficients in the model are equal to zero. Tables 3.8 and 3.9 show the
analysis of maximum likelihood estimates and odds ratio estimates respectively. The only
significant predictors of bone medication initiation appear to be the presence of bone
metastasis at diagnosis as well as having adenocarcinoma versus another type of nonsquamous NSCLC histology. The odds of being initiated on a bone therapy are 4.256
times as large for a patient who has bone metastasis present at diagnosis than for a patient
who does not present with bone metastasis at time of diagnosis [CI: 2.146,8.442].
Likewise, the odds of being initiated on a bone therapy are 3.5 times higher for those
diagnosed with adenocarcinoma as opposed to another non-squamous histology [CI: 1.11,
11.11]. Sub-group analysis of patients with bone metastasis at diagnosis did not show any
significant factors predicting bone therapy use other than histology mentioned above.
Table 3.7 Likelihood Ratio
Testing Global Null Hypothesis: BETA=0
Test

Chi-Square

DF

Pr > ChiSq

Likelihood Ratio

31.4826

8

0.0001

Score

31.4143

8

0.0001

Wald

27.3034

8

0.0006
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Table 3.8 Analysis of Maximum Likelihood Estimates
Parameter

DF

Estimate

Standard
Error

Wald
Chisquare

Pr >
Chisq

Intercept

1

-2.0668

0.4288

23.2315

<0.0001

Diagnosis age

1

-0.0267

0.0172

2.4018

0.1212

Sex (male vs
female)

1

-0.1931

0.3455

0.3124

0.5762

Rural vs Urban

1

0.2058

0.368

0.3127

0.576

Squamous cell vs
Adenocarcinoma

1

0.00802

0.3851

0.0004

0.9834

Other Histology vs
Adenocarcinoma

1

-0.6322

0.4072

2.4104

0.1205

Bonemets (1 vs 0)

1

0.7242

0.1747

17.1822

<0.0001

Brainmets

1

0.00958

0.3534

0.0007

0.9784

Livermets

1

0.2481

0.4351

0.3252

0.5685

Table 3.9 Odds Ratio Estimates
Effect

Point Estimate

95% Wald
Confidence Limits

Diagnosis age

0.974

0.941

1.007

Sex (male vs female)

0.824

0.419

1.623

Rural vs Urban

1.229

0.597

2.527

Squamous cell vs
Adenocarcinoma

0.54

0.188

1.552

Other histology vs
Adenocarcinoma

0.285

0.09

0.897

Bonemets (1 vs 0)

4.256

2.146

8.442

Brainmets

1.01

0.505

2.018

Livermets

1.282

0.546

3.007
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CHAPTER 4. DISCUSSION
To our knowledge, this is the first study assessing the incidence of antiresorptive
bone therapy utilization in EHR linked to cancer registry data since the approval of
denosumab and several targeted and immunotherapies for metastatic NSCLC. This study
is an important assessment of facility implementation of supportive care in the metastatic
NSCLC population as the life expectancy of this population continues to increase.
To begin, the population breakdown from KCR aligns well with the national
averages for lung cancer. 24,122 total cancer cases were diagnosed or treated at UKHC
between 1/01/2013 – 1/31/2020. Of those cancer cases, 3497 or approximately 14.5%
were lung cancer. This aligns with the national average where lung cancer comprises of
approximately 13% of all cancer cases [1, 3, 15]. Of those cases, 3004 or ~86% were
non-small cell lung cancer, again aligning with the national average of 85%. In this data
set 39% of patients were stage IV. This is lower than the national average where 57% of
cancer cases are diagnosed as metastatic but remains logical as UK is the largest referral
cancer center in Kentucky. As UK contains many specialists and expert surgeons,
numerous earlier stage lung cancer patients may be referred to UK for initial surgical
resection, increasing the proportion of non-metastatic to metastatic cases. Our dataset
correlation corresponding to the national average corroborates the accuracy and
completeness of the KCR data set.
Most of the descriptive statistics performed on the data set align with national SEER
averages and expectations. A few measurements that deviate from expectations include
the percent of metastasis at diagnosis which appear to be higher than the national average
for bone and brain metastasis and lower for liver. The higher averages may again be due
to UK’s nature as a referral center.
The population break down that was intended to capture different snapshots of bone
therapy use resulted in a relatively concentric trichotomy of patients. Populations 1 and 2
were very similar in size, and population 3 was almost completely encompassed in both
groups. This shows that for most patients who received any systemic therapy at UK, it
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was the patient’s first treatment, and for those who received multiple systemic therapies
at UK, the patients likely received their first systemic treatment there as well. This
indicates that patients are more likely to be systemically treated at UK initially, and then
referred out rather than being referred in later in their course of treatment, which
increases the chance of capturing bone therapy medication use if initiated close to or on
the day of first systemic treatment.
The original population breakdown intended to separate patients who were deemed
eligible to receive antiresorptive bone therapy by using the receipt of systemic therapy as
a proxy. This is because if a metastatic NSCLC patient was deemed capable enough to
receive chemotherapy or immunotherapy, then the patient should be able to tolerate an
antiresorptive bone therapy as well. Two exceptions to this would be if a patient had a
calcium level <8.5 mg/dL or severe renal impairment. With this in mind, most all of the
patients in populations 1, 2, and 3 should have been initiated on an antiresorptive bone
therapy agent at some point during their disease treatment course. Utilization, however,
was found to be extremely low. The highest proportion of bone therapy initiation (~22%)
was found in population 3, patients who received multiple systemic therapies at UK. This
could be analogous to the fact that they received more than one systemic therapy which
may point to good treatment response and clinician opinion of a better prognosis. Or, this
may be simply due to a higher bone therapy capture rate due to increased contact points
at UK. Regardless, the initiation rate is less than optimal.
In terms of bone therapy use by year, there is a spike in bone therapy initiation in
2018, the year that this project began. As this research project stemmed from anecdotal
evidence of bone therapy underutilization from the hospital, word may have spread
leading to an increase in prescribing. Of note, no bone therapy initiation was captured in
2013, which may correspond to the fact that a large proportion of patients received their
first systemic therapy on average about 2 months after their diagnosis, and median
administration of first bone therapy another 2-3 months after that. The lack of bone
therapy use in this year may point to an extreme delay in bone therapy administration, or
to a change in the EDW structure this early in the study period, leading to incomplete
abstraction of bone therapy utilization in the years of 2013 – 2014.
29

The use of denosumab as the primary bone therapy agent is not surprising, due to the
medication’s cited efficacy over bisphosphonates and rapid administration time. Selection
of bone therapy agent, if given in the outpatient setting, is highly dependent on patient
insurance and prior authorization. If given inpatient, the less expensive/generic
medication is more likely to be used.
The primary factor predicting bone therapy use was bone metastasis at diagnosis.
This is not surprising, as the primary purpose of antiresorptive bone therapies is to
decrease skeletal related events, which occur at a much higher rate in patients with bone
metastasis. This however, should not limit the use of these agents to this patient
population, as all metastatic lung cancer patients are at risk of developing bone metastasis
and subsequently SRE’s throughout the disease course. The results of this study indicate
the need for further dissemination of information regarding skeletal related event
morbidity in metastatic lung cancer patients, with the potential implementation of new
order sets or clinical decision support systems to increase bone therapy utilization.
Study Strengths and Limitations
There are several strengths and limitations with the use of this KCR-EHR linked
dataset. To begin, as the Kentucky Cancer Registry data collects information regarding
all cancer cases around the state, we can be confident that we are catching most all lung
cancer cases of any patient seen at University of Kentucky during any point of their
cancer diagnosis or treatment – regardless if this was the patient’s primary healthcare
facility. Furthermore, the Kentucky Cancer Registry Data is not based on claims which
would limit the population of interest to only those who are privately insured or have
Medicare. (A stated limitation of the previous studies cited above). Also, the KCR dataset
is structured with a set classification criterion for each variable, leading to a level of
standardization amongst all patients. As long as a patient continues to seek care in
Kentucky, KCR should capture the continuum of their care including treatment, surgery,
biopsy, radiation, and survival information including death dates [48]. Not having
survival information is another stated limitation of many claims data studies that must use
database dropout as a proxy for death.
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The KCR dataset does have its limitations with regard to details of
therapy/surgery. For example, for patient X, treatment 1 may be classified as a ‘nondefinitive surgery’. This is highly non-specific and may be referring to the initial biopsy
procedure performed for diagnostic purposes. If this were the case, the timeline of
diagnosis to first treatment would be thrown off slightly. Also, the information in KCR is
relatively limited to the care of the patient with regards to their cancer treatment. This
means that if a patient was admitted to the hospital for a non-oncologic cause, the details
of that admission may not be captured by the dataset. Due to these stated limitations,
EHR data was used to fill in the gaps of some of the missing information. By using the
structured KCR data as the initial means of data abstraction, the base population was
narrowed down as was defined in figure 3.1 and linkage to EHR data became more
structured. Unfortunately, as aforementioned, not all of the patients labeled as UK
patients from the KCR side received all of their care at UK. To balance the need for a
decent population size and the probability of capturing bone medication use, population
stratification was necessary; however, this excluded a large proportion of patients that
may have indeed received antiresorptive bone therapy at a different facility or without
having received systemic therapy.
The strengths of the EHR data coincide with its detailed nature. Like KCR, data
from the EDW is not based on claims, and supposedly captures all events in a patient’s
hospital or outpatient visit including medications, time of administration, associated labs,
etc. The downside to the abundance of information, is that the data is often free text or
unstructured leading to a lack of relative standardization among variable fields. The
combination of KCR-EHR, however, creates a pseudo-structured dataset that helps
mitigate field uncertainty.
Lessons Learned
Very important lessons were learned regarding the use of these linked datasets.
First, an understanding of the flow of data into KCR is critical when determining validity
of variable definitions, and areas of missing information. It is important to understand
where the data comes from, how it gets categorized, the standards of data entry, and the
need for use of clinical judgment to balance data and make conclusions. KCR is
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structured to an extent, but EHR is not as standardized, so definitions need to be very
specific and encompassing to ensure cases are captured appropriately.
Future Directions
Performing a bone therapy utilization analysis in a healthcare facility with EHR
data is an extremely useful tool in comparing local practice to the national practice.
Because other studies have looked at national claims data and found low utilization
across the country, it is important to see how our facility compares. Furthermore, because
of the availability of verified survival information from the KCR portion of the data, this
data opens the door to do a survival analysis comparing groups who received bone
medications and systemic therapy to those who did not.
Access to actual laboratory test results rather than just diagnosis codes indicating
toxicities such as hypercalcemia of malignancy, or hypocalcemia or renal dysfunction
leading to discontinuation of bone therapy medication use is valuable in creating a more
detailed time to event analysis of bone therapy initiation and discontinuation.
Furthermore, this study can be expanded to include other solid tumor states (breast and
prostate) or the optimization of other quality of life improving therapies. After further
exploration of secondary aims in this KCR-EHR dataset, an updated prevalence study in
a claims database such as TRUVEN would provide useful insight into how practice has
changed nationally and how we as a facility compare.
Conclusions
For metastatic non-small cell lung cancer patients receiving their first systemic
therapy at the University of Kentucky, antiresorptive bone therapies are being
underutilized with the primary predictor of use as bone metastasis at diagnosis. This gap
in research findings and clinical practice presents an ideal opportunity for a dissemination
and implementation (D&I) protocol to take effect at UKHealthCare. It is imperative to
offer education regarding the evidence of providing intravenous antiresorptive bone
therapy to eligible patients. This research can be disseminated through seminars and
distribution of educational materials. Integration of this evidence could then take place
through the implementation of an IV bone therapy stewardship program. Additionally,
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the implementation of a departmental protocol aided by clinical decision support systems
that streamline the evidence-based selection of bone therapy agent, appropriate dosing,
and frequency can ensure a patient does not get omitted from supportive care therapy
considerations.

© 2020 Copyright: Noor A. Naffakh
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APPENDICES
APPENDIX 1. KCR Definitions
Link to full KCR data dictionary: https://confluence.kcr.uky.edu/display/KAM
Select Categories Code Description
Lung topography C340 Main bronchus Carina Hilum Bronchus intermedius
C341 Upper lobe, lung Lingula Apex Pancoast tumor
C342 Middle lobe, lung (Right lung only)
C343 Lower lobe, lung Base

Mets at Dx –
Bone

Summary Stage
1977

C348
C349
0
1
2

Overlapping lesion of lung
Lung, NOS Bronchus, NOS
None, no bone metastases
Yes; distant bone metastases
Not applicable

3

Unknown whether bone is an involved metastatic site. Not
documented in patient record

0
1
2

In-situ/non-invasive malignant tumor.
Localized - tumor is confined to the organ of origin.
Regional by direct extension - tumor has spread by direct
extension to immediately adjacent tissues or organs.
Regional to lymph nodes - tumor has spread into lymph
nodes regional to the primary site of origin.
Regional by both direct extension and regional lymph
nodes.
Regional, NOS - tumor is regionally spread, but the extent
of regional spread cannot be determined, or is not specified.
Distant metastasis - a tumor that has spread beyond the
immediately adjacent tissues and has developed secondary
or metastatic tumors or is systemic.
Unknown/Unstageable

3
4
5
7
9
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APPENDIX 2. UKEDW Data Definitions
Skeletal Related Event Definitions:
•
•
•
•

pathological fracture
radiotherapy to the bone (procedure of interest as proxy for SRE)
surgery to bone (procedure of interest as proxy for SRE)
spinal cord compression

ICD-9 and HCPCs codes used from Table 4 of Measurement of skeletal related events in
SEER-Medicare: a comparison of claims-based methods. [50]
IV Antiresorptive Bone Medications:
Drug Name

Common
Brand
Names

HCPCS
Code

HCPCS
code
Dosage

IV Zoledronic Acid

Zometa,
Reclast

J3489

1 mg

Typical dose = 4 mg
every 3-4 weeks

IV Pamidronate
disodium

Aredia

J2430

30 mg

Typical dose varies

IV Denosumab

Xgeva,
Prolia

J0897

1 mg

Typical dose = 120 mg
every 4weeks
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Typical Dosing (varies
frequently)

APPENDIX 3. Population Scenario Visualizations
Scenario 1: Patient did not receive any systemic therapy after diagnosis but did have a
contact point at UK (this may have been for diagnosis, surgery, biopsy, or
radiation) and patient may have opted for best supportive care or hospice.

Scenario 2: Received Systemic Therapy (Chemotherapy or Immunotherapy) After
Diagnosis
Scenario 2A: No systemic therapies at UK (may have been diagnosed of treated
surgically at UK, but systemic treatment was received elsewhere)
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Scenario 2B: At least one systemic treatment at UK
Scenario 2B1: First systemic treatment at UK

Scenario 2B2: Multiple systemic treatments at UK (For most patients it was their first
and subsequent treatments)

(Three patients were likely transferred to UK after receiving their first systemic
treatment elsewhere)
OSH: Outside Hospital
UK: University of Kentucky
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APPENDIX 4. Coding Definitions
Geographic
Bealecode2013 description
Classification
Rural

•
•
•
•

Urban population of 20,000 or more, not adjacent to a metro area
Urban population of 2,500 to 19,999, not adjacent to a metro area
Rural, not adjacent to a metro area
Counties in metro areas of fewer than 250,000 population' then
RUC

Urban

•
•
•
•
•

Urban population of 20,000 or more, adjacent to a metro area
Urban population of 2,500 to 19,999, adjacent to a metro area
Rural, adjacent to a metro area
Counties in metro areas of 250,000 to 1 million population
Counties in metro areas of 1 million population or more

Unknown

•

Outside of state of reporting institution

Histology
Classification

Histology Description

Adenocarcinoma •
•
•
•
•
•
•
•
•

Adenocarcinoma, nos
Papillary adenocarcinoma, nos
Mucinous adenocarcinoma
Adenosquamous carcinoma
Adenocar.w/neroendocr different
Adendocar w/mxd subtypes
Acinar cell cystadenocarcinoma
Invasive mucinous adenocarcinoma
Mucin-producing adenocarcinoma

Squamous Cell
Carcinoma

•
•

Squamous cell carcinoma, nos
Basaloid squamous cell ca

Other

•
•
•
•
•
•
•

Large cell neuroendocrine ca
Non-sm cell carcinoma
Carcinoma, nos
Neoplasm, malignant
Neuroendocrine carcinoma, nos
Squam.cell carcin., keratin. Nos
Carcinoid tumor, nos
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Histology
Classification

Histology Description

Other (cont.)

•
•
•
•
•
•
•
•
•
•
•
•

Tobacco Use

Giant cell carcinoma
Large cell carcinoma, nos
Papillary carcinoma, nos
Signet ring cell carcinoma
Spindle cell carcinoma
Acinar cell carcinoma
Atypical carcinoid tumor
Carcinoma, anaplastic, nos
Carcinoma, undiffer., nos
Carcinosarcoma, nos
Metaplastic carcinoma, nos
Pleomorphic carcinoma

Description

Cigarette smoker

•

Cigarette smoker

Other tobacco user

•
•
•

Mixed tobacco pro
Cigar/pipe smoker
Smokeless tobacco

Never tobacco user

•

Never used

Unknown

•

Unkn. /not recorded
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